Effects of UK 69 578: a novel atriopeptidase inhibitor.
UK 69 578 is a competitive inhibitor of endopeptidase 24.11 (the enzyme that degrades atrial natriuretic factor) in vitro. In vivo, UK 69 578 has renal and cardiovascular effects similar to low-dose atrial natriuretic factor infusion, and may be a useful agent in hypertension and heart failure.
Northridge
D B
DB
Department of Cardiology, Western Infirmary, Glasgow.
Jardine
A G
AG
Alabaster
C T
CT
Barclay
P L
PL
Connell
J M
JM
Dargie
H J
HJ
Dilly
S G
SG
Findlay
I N
IN
Lever
A F
AF
Samuels
G M
GM
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000037:antagonists & inhibitors* / Q000097:blood; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy; D003509:Cyclohexanecarboxylic Acids; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D009392:Nephrectomy; D015260:Neprilysin / Q000037:antagonists & inhibitors* / Q000097:blood / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D003509:Cyclohexanecarboxylic Acids; C060942:candoxatrilat; D009320:Atrial Natriuretic Factor; D015260:Neprilysin